Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Inclusion Criteria: All participants Participants must weigh at least 50 kg and no more than 120 kg and must have a body mass index (BMI) within the range of 18.0 to 38.0 kg/m2, inclusive, for healthy participants. Must be a non-smoker or and agree to remain a non-smoker from screening until the End of Study. Group 1 •eGFR as determined by Chronic Kidney Disease Epidemiology Collaboration \[CKD EPI\] equation and conversion within normal range as determined by GFR 90 mL/min at screening and baseline. Groups 2 to 4 * Participants with different levels of impaired renal function satisfying criteria for renal impairment as determined at screening by the eGFR at screening * Participants must have documented stable renal disease without evidence of renal progressive disease Exclusion Criteria: All Participants * Use of drugs (prescription, non-prescription and herbal remedies such as St John's wort), within 4 weeks prior to dosing until completion of the End of Study Visit. * Participant has received a renal transplant at any time in the past and is on immunosuppressant therapy Left ventricular ejection fraction (LVEF) \< 50% or below the institutional standard lower limit, at screening or baseline. * Uncontrolled hypertension despite medical treatment at screening or baseline. Group 1 * Significant illness, which has not been resolved within 2 weeks prior to dosing of study treatment. * History or presence of renal disease or kidney injury Groups 2, 3 and 4 * Severe albuminuria * Other laboratory values grade 2 severity according to NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) * Participants undergoing any method of dialysis. * Participants with renal impairment due to hepatic disease (hepatorenal syndrome). Other protocol-defined inclusion/exclusion criteria may apply